Literature DB >> 23580473

CCRL2, a fringe member of the atypical chemoattractant receptor family.

Annalisa Del Prete1, Raffaella Bonecchi, Annunciata Vecchi, Alberto Mantovani, Silvano Sozzani.   

Abstract

The term atypical chemoattractant receptors is generally used to refer to a subset of G-protein-coupled receptors devoid of chemotactic activity and characterized by the ability to scavenge chemotactic factors from the inflammatory milieu. However, emerging evidence suggests that this class of receptors is heterogeneous in function. In this Viewpoint, we discuss the properties of CCRL2, a molecule devoid of ligand scavenging functions and suggested to regulate leukocyte recruitment by alternative mechanisms.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23580473     DOI: 10.1002/eji.201243179

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  19 in total

1.  The human chemokine receptor CCRL2 suppresses chemotaxis and invasion by blocking CCL2-induced phosphorylation of p38 MAPK in human breast cancer cells.

Authors:  Lei-Ping Wang; Jun Cao; Jian Zhang; Bi-Yun Wang; Xi-Chun Hu; Zhi-Min Shao; Zhong-Hua Wang; Zhou-Luo Ou
Journal:  Med Oncol       Date:  2015-10-20       Impact factor: 3.064

2.  Chemerin C9 peptide induces receptor internalization through a clathrin-independent pathway.

Authors:  Jun-xian Zhou; Dan Liao; Shuo Zhang; Ni Cheng; Hui-qiong He; Richard D Ye
Journal:  Acta Pharmacol Sin       Date:  2014-03-24       Impact factor: 6.150

3.  The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance.

Authors:  Annalisa Del Prete; Francesca Sozio; Tiziana Schioppa; Andrea Ponzetta; William Vermi; Stefano Calza; Mattia Bugatti; Valentina Salvi; Giovanni Bernardini; Federica Benvenuti; Annunciata Vecchi; Barbara Bottazzi; Alberto Mantovani; Silvano Sozzani
Journal:  Cancer Immunol Res       Date:  2019-09-04       Impact factor: 11.151

Review 4.  Chemokine and chemotactic signals in dendritic cell migration.

Authors:  Laura Tiberio; Annalisa Del Prete; Tiziana Schioppa; Francesca Sozio; Daniela Bosisio; Silvano Sozzani
Journal:  Cell Mol Immunol       Date:  2018-03-21       Impact factor: 11.530

5.  Anti-Inflammatory Effects of Cicadidae Periostracum Extract and Oleic Acid through Inhibiting Inflammatory Chemokines Using PCR Arrays in LPS-Induced Lung inflammation In Vitro.

Authors:  Jung-Hee Hong; Young-Cheol Lee
Journal:  Life (Basel)       Date:  2022-06-08

6.  Absence of the Non-Signalling Chemerin Receptor CCRL2 Exacerbates Acute Inflammatory Responses In Vivo.

Authors:  Daniel Regan-Komito; Sophia Valaris; Theodore S Kapellos; Carlota Recio; Lewis Taylor; David R Greaves; Asif J Iqbal
Journal:  Front Immunol       Date:  2017-11-21       Impact factor: 7.561

Review 7.  Role of Atypical Chemokine Receptors in Microglial Activation and Polarization.

Authors:  Valentina Salvi; Francesca Sozio; Silvano Sozzani; Annalisa Del Prete
Journal:  Front Aging Neurosci       Date:  2017-05-26       Impact factor: 5.750

8.  New nomenclature for atypical chemokine receptors.

Authors:  Françoise Bachelerie; Gerard J Graham; Massimo Locati; Alberto Mantovani; Philip M Murphy; Robert Nibbs; Antal Rot; Silvano Sozzani; Marcus Thelen
Journal:  Nat Immunol       Date:  2014-03       Impact factor: 25.606

9.  Signaling Properties of Chemerin Receptors CMKLR1, GPR1 and CCRL2.

Authors:  Olivier De Henau; Gaetan-Nagim Degroot; Virginie Imbault; Virginie Robert; Cédric De Poorter; Saria Mcheik; Céline Galés; Marc Parmentier; Jean-Yves Springael
Journal:  PLoS One       Date:  2016-10-07       Impact factor: 3.240

10.  The Atypical Receptor CCRL2 (C-C Chemokine Receptor-Like 2) Does Not Act As a Decoy Receptor in Endothelial Cells.

Authors:  Chiara Mazzotti; Vincenzo Gagliostro; Daniela Bosisio; Annalisa Del Prete; Laura Tiberio; Marcus Thelen; Silvano Sozzani
Journal:  Front Immunol       Date:  2017-10-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.